FierceBiotechOriginal article
{"a":[{"_":"Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival","$":{"href":"/biotech/roche-and-medilink-notch-phase-3-lung-cancer-win-trail-gsk-cross-trial-survival","hreflang":"en"}}]}
Phase 3positiveB7-H3-directed ADCPositive
AI Analysis
Summary
MediLink and Roche's B7-H3-directed ADC met its primary endpoint in a phase 3 small-cell lung cancer trial, though median overall survival trailed GSK's competing asset.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Primary endpoint met; median overall survival fell short of GSK rival asset
Importance:7/10
Sentiment:
0.30
phase 3lung cancerADCantibody-drug conjugatepartnership
Related Companies
Read the original article
Published by FierceBiotech on September 14, 2026 5:11 AM